Christopher G. Dove

1.1k total citations
9 papers, 764 citations indexed

About

Christopher G. Dove is a scholar working on Immunology, Oncology and Public Health, Environmental and Occupational Health. According to data from OpenAlex, Christopher G. Dove has authored 9 papers receiving a total of 764 indexed citations (citations by other indexed papers that have themselves been cited), including 5 papers in Immunology, 2 papers in Oncology and 2 papers in Public Health, Environmental and Occupational Health. Recurrent topics in Christopher G. Dove's work include Immunodeficiency and Autoimmune Disorders (3 papers), T-cell and B-cell Immunology (3 papers) and Immune Cell Function and Interaction (3 papers). Christopher G. Dove is often cited by papers focused on Immunodeficiency and Autoimmune Disorders (3 papers), T-cell and B-cell Immunology (3 papers) and Immune Cell Function and Interaction (3 papers). Christopher G. Dove collaborates with scholars based in United States, India and Canada. Christopher G. Dove's co-authors include Helen C. Su, Jeremiah C. Davis, Ravindra Majeti, Kévin Contrepois, Daniel Bernstein, Siddhita D. Mhatre, Ling Liu, Marie E. Migaud, M Snyder and Joshua D. Rabinowitz and has published in prestigious journals such as Proceedings of the National Academy of Sciences, The Journal of Experimental Medicine and SHILAP Revista de lepidopterología.

In The Last Decade

Christopher G. Dove

8 papers receiving 759 citations

Peers

Countries citing papers authored by Christopher G. Dove

Since Specialization

Citations

This map shows the geographic impact of Christopher G. Dove's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Christopher G. Dove with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Christopher G. Dove more than expected).

Fields of papers citing papers by Christopher G. Dove

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Christopher G. Dove. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Christopher G. Dove. The network helps show where Christopher G. Dove may publish in the future.

Co-authorship network of co-authors of Christopher G. Dove

This figure shows the co-authorship network connecting the top 25 collaborators of Christopher G. Dove. A scholar is included among the top collaborators of Christopher G. Dove based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Christopher G. Dove. Christopher G. Dove is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

9 of 9 papers shown

#	Work	Indexed citations
1	MYC-driven synthesis of Siglec ligands is a glycoimmune checkpoint 2023 ·Proceedings of the National Academy of Sciences ·Benjamin Smith, Anja Deutzmann, (unknown), (unknown), Renumathy Dhanasekaran, Christopher G. Dove, Delaney K. Sullivan, Simon Wisnovsky, Jessica C. Stark, John V. Pluvinage, Srividya Swaminathan, Nicholas M. Riley, Anand Rajan, Ravindra Majeti, Dean W. Felsher, Carolyn R. Bertozzi	40
2	Reprogramming Cancer into Antigen-Presenting Cells as a Novel Immunotherapy 2023 ·Cancer Discovery ·Miles H. Linde, Amy C. Fan, Thomas Köhnke, Aaron C. Trotman-Grant, (unknown), (unknown), (unknown), Naomi L. Haddock, (unknown), Eric J. Gars, Melissa Stafford, Payton L. Marshall, Christopher G. Dove, Ian L. Linde, Niklas Landberg, (unknown), Robbie G. Majzner, Tian Yi Zhang, Ravindra Majeti	33
3	Macrophage de novo NAD+ synthesis specifies immune function in aging and inflammation 2018 ·Nature Immunology ·Paras S. Minhas, Ling Liu, Peter K. Moon, Amit U. Joshi, Christopher G. Dove, Siddhita D. Mhatre, Kévin Contrepois, Qian Wang, (unknown), Michael Coronado, Daniel Bernstein, M Snyder, Marie E. Migaud, Ravindra Majeti, Daria Mochly‐Rosen, Joshua D. Rabinowitz, Katrin I. Andreasson	355
4	Reprogramming of primary human philadelphia chromosome-positive B cell acute lymphoblastic leukemia cells into nonleukemic macrophages 2016 ·Experimental Hematology ·Christopher G. Dove, Miles H. Linde, (unknown), Ravindra Majeti	0
5	Reprogramming of primary human Philadelphia chromosome-positive B cell acute lymphoblastic leukemia cells into nonleukemic macrophages 2015 ·Proceedings of the National Academy of Sciences ·James Scott McClellan, Christopher G. Dove, Andrew J. Gentles, Christine E. Ryan, Ravindra Majeti	44
6	DOCK8 regulates lymphocyte shape integrity for skin antiviral immunity 2014 ·The Journal of Experimental Medicine ·Qian Zhang, Christopher G. Dove, Jyh Liang Hor, H. Moses Murdock, Dara M. Strauss‐Albee, Jordan Garcia, Judith N. Mandl, (unknown), Huie Jing, Devon Chandler‐Brown, (unknown), Greg Crawford, Helen Matthews, Alexandra F. Freeman, Richard J. Cornall, Ronald N. Germain, Scott N. Mueller, Helen C. Su	122
7	Somatic reversion in dedicator of cytokinesis 8 immunodeficiency modulates disease phenotype 2014 ·Journal of Allergy and Clinical Immunology ·Huie Jing, Qian Zhang, Yu Zhang, Brenna J. Hill, Christopher G. Dove, Erwin W. Gelfand, T. Prescott Atkinson, Gülbû Uzel, Helen Matthews, Peter Mustillo, David B. Lewis, (unknown), I. Celine Hanson, Ashish Kumar, Raif S. Geha, Daniel C. Douek, Steven M. Holland, Alexandra F. Freeman, Helen C. Su	53
8	Genetic, Clinical, and Laboratory Markers for DOCK8 Immunodeficiency Syndrome 2010 ·SHILAP Revista de lepidopterología ·Jeremiah C. Davis, Christopher G. Dove, Helen C. Su	66
9	Genetic, Clinical, and Laboratory Markers for DOCK8 Immunodeficiency Syndrome 2010 ·Disease Markers ·Jeremiah C. Davis, Christopher G. Dove, Helen C. Su	51

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact